Peptide Receptor Radionuclide Therapy (PRRT) of Medullary and Nonmedullary Thyroid Cancer Using Radiolabeled Somatostatin Analogues

Semin Nucl Med. 2016 May;46(3):215-24. doi: 10.1053/j.semnuclmed.2016.01.010.


As therapeutic options in advanced medullary and non-iodine avid differentiated (nonmedullary) thyroid cancers are limited and associated with significant toxicity, targeting of somatostatin receptors (SSTRs) for internal radiation therapy provides a promising option. Theranostics (therapy and diagnosis) using radiolabeled somatostatin analogues has proved to be a milestone in the management of SSTR-expressing tumors. Peptide receptor radionuclide therapy using (177)Lu-labeled or (90)Y-labeled somatostatin analogues may have a significant role in the management of medullary and nonmedullary thyroid cancers in those patients where PET/CT with (68)Ga-labeled somatostatin analogues demonstrates significant SSTR expression.

Publication types

  • Review

MeSH terms

  • Animals
  • Carcinoma, Neuroendocrine / pathology
  • Carcinoma, Neuroendocrine / radiotherapy*
  • Drug Resistance
  • Humans
  • Isotope Labeling
  • Receptors, Somatostatin / metabolism*
  • Somatostatin / analogs & derivatives*
  • Somatostatin / metabolism
  • Somatostatin / therapeutic use*
  • Thyroid Neoplasms / pathology
  • Thyroid Neoplasms / radiotherapy*


  • Receptors, Somatostatin
  • Somatostatin

Supplementary concepts

  • Thyroid cancer, medullary